<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899066</url>
  </required_header>
  <id_info>
    <org_study_id>yanghs20130627</org_study_id>
    <nct_id>NCT01899066</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Lucentis in the Treatment of Retinoblastoma</brief_title>
  <official_title>Lucentis in the Treatment of Retinoblastoma - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical efficacy of intravitreal injections of Ranibizumab
      (Lucentis) together with chemotherapy in the treatment of Retinoblastoma as compared to
      chemotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a phase II open label interventional case series. Patients with
      retinoblastoma will be randomized to receive chemotherapy with or without intravitreal
      ranibizumab at a dose of 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana
      injection on a monthly basis for a total duration of therapy of 6 months. Patients will be
      followed for 24 months .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
    <description>measure the mortality rate for the two groups(Cancer-related death and non-Cancer-related death) at two years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Lucentis(intravitreal injection) in the Treatment of Retinoblastoma</measure>
    <time_frame>two years</time_frame>
    <description>measure the tumor size and new vessels by ultrasonographyï¼Œfundus photography and fundoscopy before each treatment, and 1,3,6,9,12,18,24 months after the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Lucentis; chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.
Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis, chemotherapy</intervention_name>
    <description>Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.
chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.</description>
    <arm_group_label>Lucentis; chemotherapy</arm_group_label>
    <other_name>Ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>vincristine;</other_name>
    <other_name>carboplatin;</other_name>
    <other_name>etoposide.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Definite characteristic signs of retinoblastoma,Group D base on Intraocular
             International Retinoblastoma classify, IIRC.

        Exclusion Criteria:

          -  History of surgical intervention for retinoblastoma in the study eye.

          -  Any previous disease in the study eye.

          -  Previous participation in any studies of investigational drugs within 1 month
             preceding Day 0 (excluding vitamins and minerals).

          -  Previous participation in a clinical trial (for either eye) involving anti angiogenic
             drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huasheng Yang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huasheng Yang, M.D, PHD</last_name>
    <phone>+8620-87331539</phone>
    <email>yanghs64@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>+8620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huasheng Yang, MD,PHD</last_name>
      <phone>+862087331539</phone>
      <email>yanghs64@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>May 10, 2014</last_update_submitted>
  <last_update_submitted_qc>May 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huasheng Yang</investigator_full_name>
    <investigator_title>Efficacy Study of Lucentis in the Treatment of Retinoblastoma</investigator_title>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

